1 month Halozyme Therapeutics (NASDAQ:HALO) Earns “Buy” Rating from HC WainwrightMarketBeat
HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Friday.
XHC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Friday.
X